PMID- 35594278
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20220630
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 5
DP  - 2022
TI  - Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for 
      inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A 
      meta-analysis.
PG  - e0268779
LID - 10.1371/journal.pone.0268779 [doi]
LID - e0268779
AB  - BACKGROUND: The efficacy and safety of stereotactic body radiotherapy (SBRT) plus 
      transcatheter arterial chemoembolization (TACE) versus SBRT or TACE 
      alone(monotherapy) for hepatocellular carcinoma (HCC) patients with portal vein 
      tumour thrombus (PVTT) remains controversial. This meta-analysis was performed to 
      provide more powerful evidence for clinical strategies in inoperable HCC with 
      PVTT. METHODS: We searched the PubMed, EMBASE, Web of Science, Cochrane Library, 
      China Biology Medicine (CBM), China National Knowledge Infrastructure (CNKI), VIP 
      Journal Integration Platform (VIP), and WanFang databases for eligible studies. 
      We pooled the results of 1- and 2-year overall survival rates (OSRs), objective 
      response rates (ORRs), and adverse events (AEs) between the two groups and 
      performed a subgroup meta-analysis for study type, control group, treatment 
      order, and the interval between SBRT and TACE. RESULTS: Nine studies with 10 
      cohorts involving 938 patients were included in our meta-analysis. SBRT plus TACE 
      yielded significantly higher 1-year OSR (RR, 1.52[95% CI, 1.33-1.74]), 2-year OSR 
      (RR, 2.00 [95% CI: 1.48-2.70]), ORR (RR = 1.22 [95% CI, 1.08-1.37]), and a lower 
      progression disease (PD) rate (RR = 0.45 [95% CI:0.26-0.79]) than monotherapy. No 
      significant differences were detected in CR, PR, SD, or AEs between the two 
      groups. Subgroup analysis regarding study type, control group, and treatment 
      order indicated that compared with monotherapy, the combination of SBRT with TACE 
      was associated with an increase in 1- and 2-year OSRs but not in ORR. In regard 
      to the interval between SBRT and TACE, subgroup analysis found that the 
      combination therapy for patients with an SBRT-TACE interval <28 days was 
      preferable to monotherapy in the 1- and 2-year OSRs, and ORR. However, for 
      patients with an SBRT-TACE interval >/=28 days, no obvious distinctions were 
      observed in the 1-year OSR, 2-year OSR, or ORR between the two groups. 
      CONCLUSION: The combination of SBRT with TACE appears to be better than 
      monotherapy in treating HCC with PVTT and should be recommended for inoperable 
      HCC patients with PVTT.
FAU - Zhang, Xiao-Fei
AU  - Zhang XF
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Lai, Lin
AU  - Lai L
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
AD  - Department of Radiotherapy, Tumor Hospital of Guangxi Medical University, 
      Nanning, China.
FAU - Zhou, Hui
AU  - Zhou H
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Mo, Yuan-Jun
AU  - Mo YJ
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Lu, Xu-Quan
AU  - Lu XQ
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Liu, Min
AU  - Liu M
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Lu, Yun-Xin
AU  - Lu YX
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
FAU - Hou, En-Cun
AU  - Hou EC
AUID- ORCID: 0000-0002-6458-002X
AD  - Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of 
      Chinese Medicine, Nanning, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20220520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Carcinoma, Hepatocellular/drug therapy/therapy
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/therapy
MH  - Portal Vein/pathology
MH  - *Radiosurgery
MH  - *Thrombosis/etiology
MH  - Treatment Outcome
PMC - PMC9122181
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/05/21 06:00
MHDA- 2022/05/25 06:00
PMCR- 2022/05/20
CRDT- 2022/05/20 13:34
PHST- 2021/10/05 00:00 [received]
PHST- 2022/05/06 00:00 [accepted]
PHST- 2022/05/20 13:34 [entrez]
PHST- 2022/05/21 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/05/20 00:00 [pmc-release]
AID - PONE-D-21-32103 [pii]
AID - 10.1371/journal.pone.0268779 [doi]
PST - epublish
SO  - PLoS One. 2022 May 20;17(5):e0268779. doi: 10.1371/journal.pone.0268779. 
      eCollection 2022.